Parameters for pesticide QSAR and PBPK/PD models for human risk assessment /

Bibliographic Details
Corporate Authors: American Chemical Society, American Chemical Society. Division of Agrochemicals
Other Authors: Knaak, James B., Timchalk, Charles, Tornero-Velez, Rogelio
Format: eBook
Language:English
Language Notes:English.
Published: Washington, DC : American Chemical Society, ©2012.
Series:ACS symposium series ; 1099.
Subjects:
Online Access:Connect to the full text of this electronic book
Table of Contents:
  • Parameters for pesticide QSAR and PBPK/PD models to inform human risk assessments
  • Chiral chemistry and toxicity assessments for pyrethroid pesticides
  • Direct chiral separation of pyrethroid isomers by HPLC with chiral stationary phases
  • Biotransformation and enzymes responsible for metabolism of pyrethroids in mammals
  • Characterization of potential age-related differences in pyrethroid pharmacokinetics
  • 15 factors of percutaneous penetration of pesticides
  • Percutaneous absorption of pesticide formulations
  • Human metabolic interactions of pesticides : inhibition, induction and activation
  • Paraoxonase 1 (PON1) status in risk assessment for organophosphate exposure and pharmacokinetics
  • Carboxylesterases : a multifunctional enzyme involved in pesticide and lipid metabolism
  • Behavioral changes in adult and young rats as indications of cholinesterase inhibition
  • Comparison of esterase sensitivity, metabolic efficiency, and toxicity levels of two organophosphorus insecticides, parathion and chlorpyrifos
  • Regional brain dosimetry for the organophosphorus insecticide chlorpyrifos in the preweanling rat
  • Pyrethroid actions on sodium channels : isoform and species specificity
  • In vitro and in vivo experimental data for development and use of pharmacokinetic models for in vitro to in vivo extrapolation of pyrethroid insecticides
  • In silico strategies for modeling stereoselective metabolism of pyrethroids
  • Quantitative structure-activity relationships for organophosphate enzyme inhibition
  • Computational approaches for developing informative prior distributions for bayesian calibration of PBPK models
  • Use of cytochrome P450-specific parameters and human biomarker data to develop a human physiologically based pharmacokinetic/pharmacodynamic model for dermal chlorpyrifos exposure
  • Use of in vitro data in PBPK models : an example of in vitro to in vivo extrapolation with carbaryl.